GSK’s RSV vaccine gets approval of advisory panel

GSK’s vaccine for respiratory syncytial virus won the support of a key panel of US regulatory advisers for use in people 60 and older, as the drug maker races against Pfizer to bring to market the first vaccine for RSV. The panel of 12 outside advisers to the Food and Drug Administration voted unanimously on Wednesday that GSK’s data show the Arexvy vaccine is effective. The same committee voted earlier 10-2 that company data show the shot is safe. The Vaccines and Related Biological Products Advisory Committee’s recommendations aren’t binding, but are often followed by the agency. Pfizer won the endorsement of the same panel on Tuesday.